124 related articles for article (PubMed ID: 3096324)
1. Combined effects of buserelin, estradiol and tamoxifen on the growth of MCF-7 human breast cancer cells in vitro.
Foekens JA; Henkelman MS; Fukkink JF; Blankenstein MA; Klijn JG
Biochem Biophys Res Commun; 1986 Oct; 140(2):550-6. PubMed ID: 3096324
[TBL] [Abstract][Full Text] [Related]
2. Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxy-tamoxifen isomers in MCF-7 human breast cancer cells.
Katzenellenbogen BS; Norman MJ; Eckert RL; Peltz SW; Mangel WF
Cancer Res; 1984 Jan; 44(1):112-9. PubMed ID: 6537799
[TBL] [Abstract][Full Text] [Related]
3. Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1.
Lykkesfeldt AE; Madsen MW; Briand P
Cancer Res; 1994 Mar; 54(6):1587-95. PubMed ID: 8137264
[TBL] [Abstract][Full Text] [Related]
4. Direct inhibitory effect of a luteinizing hormone-releasing hormone agonist on MCF-7 human breast cancer cells.
Blankenstein MA; Henkelman MS; Klijn JG
Eur J Cancer Clin Oncol; 1985 Dec; 21(12):1493-9. PubMed ID: 3938397
[TBL] [Abstract][Full Text] [Related]
5. Estradiol-independent growth of a subline of MCF-7 human breast cancer cells in culture.
Nawata H; Chong MT; Bronzert D; Lippman ME
J Biol Chem; 1981 Jul; 256(13):6895-902. PubMed ID: 7240250
[TBL] [Abstract][Full Text] [Related]
6. Combined effects of estradiol, leuprorelin, tamoxifen and medroxyprogesterone acetate on cell growth and steroid hormone receptors in breast cancer cells.
Sica G; Iacopino F; Robustelli della Cuna G; Marchetti P; Marini L
J Cancer Res Clin Oncol; 1994; 120(10):605-9. PubMed ID: 7929532
[TBL] [Abstract][Full Text] [Related]
7. Direct effects of luteinizing hormone-releasing hormone agonists and antagonists on MCF-7 mammary cancer cells.
Segal-Abramson T; Kitroser H; Levy J; Schally AV; Sharoni Y
Proc Natl Acad Sci U S A; 1992 Mar; 89(6):2336-9. PubMed ID: 1312718
[TBL] [Abstract][Full Text] [Related]
8. Antiestrogenic action of 3-hydroxytamoxifen in the human breast cancer cell line MCF-7.
Roos W; Oeze L; Löser R; Eppenberger U
J Natl Cancer Inst; 1983 Jul; 71(1):55-9. PubMed ID: 6575210
[TBL] [Abstract][Full Text] [Related]
9. Characterization of estrogen and progesterone receptors and the dissociated regulation of growth and progesterone receptor stimulation by estrogen in MDA-MB-134 human breast cancer cells.
Reiner GC; Katzenellenbogen BS
Cancer Res; 1986 Mar; 46(3):1124-31. PubMed ID: 3943090
[TBL] [Abstract][Full Text] [Related]
10. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse.
Gottardis MM; Robinson SP; Satyaswaroop PG; Jordan VC
Cancer Res; 1988 Feb; 48(4):812-5. PubMed ID: 3338079
[TBL] [Abstract][Full Text] [Related]
11. mRNA expression of the type I growth factor receptors in the human breast cancer cells MCF-7: regulation by estradiol and tamoxifen.
Revillion F; Pawlowski V; Lhotellier V; Louchez MM; Peyrat JP
Anticancer Res; 2003; 23(2B):1455-60. PubMed ID: 12820409
[TBL] [Abstract][Full Text] [Related]
12. Isolation and characterization of a tamoxifen-resistant cell line derived from MCF-7 human breast cancer cells.
Nawata H; Bronzert D; Lippman ME
J Biol Chem; 1981 May; 256(10):5016-21. PubMed ID: 7228867
[TBL] [Abstract][Full Text] [Related]
13. Antiestrogen binding in antiestrogen growth-resistant estrogen-responsive clonal variants of MCF-7 human breast cancer cells.
Miller MA; Lippman ME; Katzenellenbogen BS
Cancer Res; 1984 Nov; 44(11):5038-45. PubMed ID: 6488162
[TBL] [Abstract][Full Text] [Related]
14. Biological activity and receptor binding of a strongly interacting estrogen in human breast cancer cells.
Reiner GC; Katzenellenbogen BS; Bindal RD; Katzenellenbogen JA
Cancer Res; 1984 Jun; 44(6):2302-8. PubMed ID: 6547074
[TBL] [Abstract][Full Text] [Related]
15. Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study.
Klijn JG; Beex LV; Mauriac L; van Zijl JA; Veyret C; Wildiers J; Jassem J; Piccart M; Burghouts J; Becquart D; Seynaeve C; Mignolet F; Duchateau L
J Natl Cancer Inst; 2000 Jun; 92(11):903-11. PubMed ID: 10841825
[TBL] [Abstract][Full Text] [Related]
16. Catecholestrogens are MCF-7 cell estrogen receptor agonists.
Schütze N; Vollmer G; Tiemann I; Geiger M; Knuppen R
J Steroid Biochem Mol Biol; 1993 Dec; 46(6):781-9. PubMed ID: 8274412
[TBL] [Abstract][Full Text] [Related]
17. A direct LHRH-agonist action on cancer cells is unlikely to be the cause of response to LHRH-agonist treatment.
Slotman BJ; Poels LG; Rao BR
Anticancer Res; 1989; 9(1):77-80. PubMed ID: 2495758
[TBL] [Abstract][Full Text] [Related]
18. High progesterone receptor concentration in a variant of the ZR-75-1 human breast cancer cell line adapted to growth in oestrogen free conditions.
van den Berg HW; Martin J; Lynch M
Br J Cancer; 1990 Apr; 61(4):504-7. PubMed ID: 2139575
[TBL] [Abstract][Full Text] [Related]
19. Growth factor-like activity of phenol red preparations in the MCF-7 breast cancer cell line.
Devleeschouwer N; Body JJ; Legros N; Muquardt C; Donnay I; Wouters P; Leclercq G
Anticancer Res; 1992; 12(3):789-94. PubMed ID: 1622138
[TBL] [Abstract][Full Text] [Related]
20. Tamoxifen in the rat prevents estrogen-deficiency bone loss elicited with the LHRH agonist buserelin.
Goulding A; Gold E; Feng W
Bone Miner; 1992 Aug; 18(2):143-52. PubMed ID: 1525595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
